Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors

The New England Journal of Medicine
Johnny MahlanguRebecca Kruse-Jarres

Abstract

Emicizumab is a bispecific monoclonal antibody that bridges activated factor IX and factor X to replace the function of missing activated factor VIII, thereby restoring hemostasis. In a phase 3, multicenter trial, we investigated its use as prophylaxis in persons who have hemophilia A without factor VIII inhibitors. We randomly assigned, in a 2:2:1 ratio, participants 12 years of age or older who had been receiving episodic treatment with factor VIII to receive a subcutaneous maintenance dose of emicizumab of 1.5 mg per kilogram of body weight per week (group A) or 3.0 mg per kilogram every 2 weeks (group B) or no prophylaxis (group C). The primary end point was the difference in rates of treated bleeding (group A vs. group C and group B vs. group C). Participants who had been receiving factor VIII prophylaxis received emicizumab at a maintenance dose of 1.5 mg per kilogram per week (group D); intraindividual comparisons were performed in those who had participated in a noninterventional study. A total of 152 participants were enrolled. The annualized bleeding rate was 1.5 events (95% confidence interval [CI], 0.9 to 2.5) in group A and 1.3 events (95% CI, 0.8 to 2.3) in group B, as compared with 38.2 events (95% CI, 22.9 to 63...Continue Reading

References

Jun 9, 2001·The New England Journal of Medicine·P M Mannucci, E G Tuddenham
Apr 23, 2013·Journal of Thrombosis and Haemostasis : JTH·C H MillerUNKNOWN Hemophilia Inhibitor Research Study Investigators
Jul 17, 2013·Journal of Thrombosis and Haemostasis : JTH·F PeyvandiS Seregni
Jul 3, 2013·Blood Reviews·Massimo Franchini, Pier Mannuccio Mannucci
Jul 9, 2013·Patient Related Outcome Measures·David T EtonVictor M Montori
Oct 22, 2013·JAMA : the Journal of the American Medical Association·UNKNOWN World Medical Association
Nov 12, 2014·BMJ : British Medical Journal·Frances S Mair, Carl R May
Mar 31, 2015·British Journal of Haematology·Rolf Ljung, Nadine Gretenkort Andersson
Apr 2, 2015·Haemophilia : the Official Journal of the World Federation of Hemophilia·K W WyrwichS von Mackensen
May 26, 2016·The New England Journal of Medicine·Midori ShimaKeiji Nogami
Jul 12, 2017·The New England Journal of Medicine·Johannes OldenburgMidori Shima
Dec 7, 2017·The New England Journal of Medicine·Lindsey A GeorgeKatherine A High
Dec 12, 2017·The New England Journal of Medicine·Savita RangarajanK John Pasi

❮ Previous
Next ❯

Citations

Aug 30, 2018·The New England Journal of Medicine·Margaret V Ragni
Sep 27, 2018·Pediatric Blood & Cancer·Courtney D Thornburg
Oct 4, 2018·Expert Review of Hematology·Guy YoungSteven Pipe
Nov 16, 2018·Haemophilia : the Official Journal of the World Federation of Hemophilia·E Carlos Rodriguez-Merchan, Leonard A Valentino
Nov 22, 2018·Expert Opinion on Drug Safety·Arielle L LangerLouis Aledort
Nov 20, 2018·Expert Review of Hematology·Johnny Mahlangu
Jan 4, 2019·Haemophilia : the Official Journal of the World Federation of Hemophilia·Glenn F PierceUNKNOWN Members of the WFH Gene Therapy Round Table Program Committee and Organizing Committee
Dec 24, 2018·Expert Review of Hematology·Christine Biron-Andreani, Jean-François Schved
Feb 7, 2019·Haemophilia : the Official Journal of the World Federation of Hemophilia·Rebecca Kruse-JarresJohnny Mahlangu
Feb 13, 2019·Haemophilia : the Official Journal of the World Federation of Hemophilia·Donald F BrophyJanice Kuhn
Apr 30, 2019·Annals of Internal Medicine·Lee Goldman, Jill S Goldman
May 1, 2019·Expert Opinion on Biological Therapy·Giancarlo Castaman, Silvia Linari
May 10, 2019·British Journal of Haematology·Guy Young
May 28, 2019·Haemophilia : the Official Journal of the World Federation of Hemophilia·Szymon JanczarWojciech Mlynarski
May 28, 2019·Expert Review of Hematology·Lorraine CafuirChristine L Kempton
Jun 1, 2019·Expert Opinion on Biological Therapy·Johnny Mahlangu
Jul 23, 2019·Haemophilia : the Official Journal of the World Federation of Hemophilia·Margaret V RagniUNKNOWN Members of Working Group 1, the NHLBI State of the Science Workshop on factor VIII inhibitors: Generating a national bluepri
Jun 21, 2019·JCI Insight·Benjamin J Samelson-JonesValder R Arruda
Jul 31, 2019·Haemophilia : the Official Journal of the World Federation of Hemophilia·Glenn F PierceUNKNOWN Committee on Coagulation Products Safety Supply, Access (CPSSA) of the World Federation of Hemophilia (WFH)
Jun 9, 2019·Nature Reviews. Drug Discovery·Aran F LabrijnPaul W H I Parren
Aug 2, 2019·Journal of Thrombosis and Haemostasis : JTH·Michael MakrisPeter J Lenting
Aug 3, 2019·Haemophilia : the Official Journal of the World Federation of Hemophilia·Glaivy BatsuliRobert F Sidonio
Sep 4, 2019·Journal of Thrombosis and Haemostasis : JTH·Steven W Pipe
Sep 14, 2019·Haemophilia : the Official Journal of the World Federation of Hemophilia·Midori ShimaMasashi Taki
Apr 30, 2019·Haemophilia : the Official Journal of the World Federation of Hemophilia·Manuel CarcaoUNKNOWN Future of Immunotolerance Treatment Group
Dec 21, 2019·Haemophilia : the Official Journal of the World Federation of Hemophilia·P Vincent JenkinsWill Lester
Sep 19, 2019·Indian Journal of Pediatrics·Geetha Puthenveetil, Diane Nugent
Nov 21, 2019·Haemophilia : the Official Journal of the World Federation of Hemophilia·Patrick T EbbertMargaret V Ragni
Jan 24, 2020·Journal of Medical Economics·Keziah CookLouis P Garrison
Mar 12, 2020·Haemophilia : the Official Journal of the World Federation of Hemophilia·Naruto ShimonishiMidori Shima
Jul 10, 2019·Therapeutic Drug Monitoring·Josée Golay, Mario Regazzi
Apr 7, 2020·Haemophilia : the Official Journal of the World Federation of Hemophilia·Annette BowyerRhona Maclean
Apr 21, 2020·Haemophilia : the Official Journal of the World Federation of Hemophilia·Isabella McCaryLeslie Raffini
May 2, 2020·Haemophilia : the Official Journal of the World Federation of Hemophilia·Johnny N Mahlangu
May 12, 2020·British Journal of Haematology·Rachel RaymentUNKNOWN British Society for Haematology
May 13, 2020·Blood Advances·Peter J Lenting
May 21, 2020·Clinical Pharmacology in Drug Development·Haiyan LiChristophe Schmitt

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.

Related Papers

The New England Journal of Medicine
Johannes OldenburgMidori Shima
The New England Journal of Medicine
Michael E WechslerEGPA Mepolizumab Study Team
The New England Journal of Medicine
Gregory G SchwartzODYSSEY OUTCOMES Committees and Investigators
The New England Journal of Medicine
Jeffrey S WeberCheckMate 238 Collaborators
© 2022 Meta ULC. All rights reserved